Clearance includes percutaneous and surgical use in superficial and perforator veins. Receives U.S. FDA 510(k) Clearance for ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced its development program for PerQseal ® ...
The randomized ACCESS-TAVI study led by PD Dr. Tobias Rheude and DZHK-Prof. Michael Joner from the German Heart Center Munich and the German Center for Cardiovascular Research shows that a combined ...
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ...
Vivasure Medical Ltd. has designed a sutureless and absorbable venous vessel closure for use following percutaneous cardiovascular procedures, such as transcatheter mitral valve or tricuspid valve ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...
Please provide your email address to receive an email when new articles are posted on . The CHOICE-CLOSURE trial was presented by Mohamed Abdel-Wahab, MD, consultant cardiologist and head of the ...
Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure ...
The AMBULATE Same-Day Discharge Clinical Study Series demonstrates safe and effective use of VASCADE MVP in three studies to date, with more than 800 AF ablation patients discharged the same calendar ...
The explosion of innovation in valve replacement and repair markets is opening a huge opportunity for percutaneous vessel closure devices. Edward Lifesciences’s FDA nod for the Evoque Transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results